2023
DOI: 10.3390/cancers15061760
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

Abstract: Recent prospective clinical trial data suggest that patients with Hodgkin’s lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We describe the outcomes of PET2+ patients who continued ABVD and compare the performance of a quantitative measure based on the lesion-to-liver SUV ratio (LLS qPET2+) to that of the subjective Deauville criteria (dvPET2+). We analyzed all patients with newly diagnosed adv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 32 publications
0
3
0
1
Order By: Relevance
“…[14][15][16][17][18][19][20] However, few data are known regarding the use of iPET2 in routine clinical practice, and in particular about the real-life adoption of intensification strategies for iPET positive patients, including frequency and type of intensification therapies and related outcomes and, thus, making considerations in this regard difficult. [21][22][23][24][25] In addition, most studies (both clinical trials and real-life observational research) have been referred to advanced stage patients and, thus, possible improvements from additional research need to be investigated.…”
Section: Introductionmentioning
confidence: 99%
“…[14][15][16][17][18][19][20] However, few data are known regarding the use of iPET2 in routine clinical practice, and in particular about the real-life adoption of intensification strategies for iPET positive patients, including frequency and type of intensification therapies and related outcomes and, thus, making considerations in this regard difficult. [21][22][23][24][25] In addition, most studies (both clinical trials and real-life observational research) have been referred to advanced stage patients and, thus, possible improvements from additional research need to be investigated.…”
Section: Introductionmentioning
confidence: 99%
“…При этом у пациентов с положительными результатами промежуточной ПЭТ-КТ после 2 циклов ABVD и продолжающих получать лечение по схеме ABVD исходы терапии хуже, чем у больных, переведенных на BEACOPPesc. [48]. Если лечение кЛХ начато с режима ВЕАСОРР, необходимо учитывать некоторые особенности при интерпретации результатов промежуточного ПЭТ-КТ-сканирования, например заключающиеся в более высокой вероятности ложноположительных результатов после 2 циклов терапии.…”
Section: классическая лимфома ходжкинаunclassified
“…FDG-PET scans are rated on a scale of 1–5 with the score 1–3 indicating a favorable response or a complete metabolic response (CMR) and a score 4–5 indicating no response to treatment, condition that may require further treatment or closer monitoring [ 13 ]. In a recent study with the aim to analyze the impact of a positive iPET, patients with HL had excellent long-term outcomes regardless of iPET status; for those with DS4, the choice to intensify is debated and the DS should be integrated with other data such as level of FDG avidity [ 14 ].…”
Section: Fdg-pet In the Assessment Of Response To Frontline Therapymentioning
confidence: 99%